External Ids for BLMH Gene
Bleomycin hydrolase (BMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution; however, the only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The protein contains the signature active site residues of the cysteine protease papain superfamily. [provided by RefSeq, Jul 2008]
GeneCards Summary for BLMH Gene
BLMH (Bleomycin Hydrolase) is a Protein Coding gene. Diseases associated with BLMH include mutagen sensitivity and resistance to bleomycine in the treatment of testicular cancer. Among its related pathways are Class I MHC mediated antigen processing and presentation and Class I MHC mediated antigen processing and presentation. GO annotations related to this gene include cysteine-type peptidase activity and aminopeptidase activity.
UniProtKB/Swiss-Prot for BLMH Gene
The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity.